- Regulatory impact: The decision shows that one vaccine can face different approval standards across age groups when the supporting evidence differs.
- Clinical Quality impact: Teams must align comparator choice, endpoints, and evidence interpretation with the standard of care for each target population.
- Development impact: For adults 65 and older, approval does not close the evidence package; postmarketing evidence must still confirm clinical benefit.
One mRNA Vaccine, Two FDA Approval Paths, Here’s Why
Moderna’s regulatory journey was not straightforward. Earlier in 2026, FDA challenged the comparator strategy behind the clinical program. The issue mattered most for older adults because CDC preferentially recommends high-dose, recombinant, or adjuvanted influenza vaccines for people aged 65 and older. Therefore, FDA questioned whether evidence against a standard-dose vaccine could adequately support that population.
After further regulatory review, FDA evaluated two different evidence questions. For adults aged 50 to 64, the agency considered clinical efficacy data from the Phase III P304 trial. The study enrolled more than 40,000 adults, and mFlusiva showed 26.6% greater relative efficacy than a licensed standard-dose influenza vaccine.
However, FDA followed a different route for adults 65 and older. In that population, Moderna submitted comparative immunogenicity data against a high-dose vaccine. FDA treated those immune-response measures as surrogate endpoints reasonably likely to predict clinical benefit and linked accelerated approval to additional confirmatory evidence.
FDA’s Split Decision Changes the Evidence Strategy for Pharma Teams
The case puts comparator selection back at the center of late-stage development. A comparator that supports one population may not satisfy regulators in another when treatment standards differ. As a result, clinical and regulatory teams need to challenge comparator strategy before pivotal trials lock the evidence package.
This table shows exactly where FDA’s split approval changes the evidence burden and what each pharma team needs to protect next.
| Role | Main risk | Required actionaction | Evidence to protect | Timing |
|---|---|---|---|---|
|
Regulatory Affairs |
Comparator does not match current standard |
Reconfirm comparator strategy |
Agency advice and benefit-risk rationale |
Before filing |
|
Clinical Quality |
Endpoints cannot support the intended claim |
Strengthen endpoint governance |
Protocol, assessment and deviation records |
During Phase III |
|
Development Leadership |
Clinical benefit remains unverified |
Plan confirmatory study early |
Phase IV milestones and decisions |
Pre- and post-approval |
Approval Is Not the Finish Line: Phase IV Now Holds the Key
FDA approval gives Moderna a major regulatory milestone, but the two age groups do not reach the same evidentiary endpoint. For adults 65 and older, the confirmatory study now becomes part of the product’s regulatory lifecycle rather than a routine post-launch exercise.
Meanwhile, the next implementation question moves beyond FDA. CDC and ACIP recommendations will influence how mFlusiva enters U.S. influenza vaccination practice. For regulatory teams, the practical question is therefore clear: if one product targets populations with different standards of care, can your evidence strategy defend each population separately?
The mFlusiva case shows that comparator choice can change an approval pathway even when the product itself does not change.
Moderna’s split approval shows that regulatory complexity often continues long after a product reaches the market, especially when different populations require different evidence standards. Zamann Pharma’s Quality Management System support helps pharmaceutical teams turn those evolving expectations into stronger quality governance, clearer risk control, and more defensible compliance decisions across the product lifecycle.
Source: Pharmaceutical-Technology.Com